Skip to main content
SPARC - Logo
Innovations Inspired by life
Menu

Hamburger

  • Our Company
    • Who we are
    • History
    • Culture
    • Board of Directors
    • Leadership Team
  • OUR RESEARCH
    • Therapeutic focus
    • Delivery Technologies
    • Research Programs
    • R&D Pipeline
  • Our Medicines
    • Xelpros®
    • Elepsia® XR
  • Business Development
    • Strategy
    • Partner with us
  • Accreditations And Approvals
    • Good Laboratory Practice
  • Investors
    • Who we are
    • Financials
    • Annual reports
    • Presentations
    • Chairman's Speech
    • Committees of BOD's
    • Shareholding pattern
    • Announcements & Disclosures
    • Policies & Codes
    • Listing Information
    • Board of Directors
    • FAQ’s, Guide Book and Forms for Shareholders
    • Investors Contact
    • Go green
    • IEPF
  • Media
    • Press Releases
    • Presentations
  • Careers
    • Overview
    • Apply Now
  • Contact Us
Our Company » History

Our History left Menu

  • Our Company
    • Who we are
    • History
    • Culture
    • Board of Directors
    • Leadership Team

History

  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2007
  • 2006
  •  

    2020

    • Entered into a worldwide license agreement for SCD-044 with Sun Pharma
    • Entered into collaboration with the University of Michigan to kickstart research and development of potential new medications
  •  

    2019

    • Entered into licensing agreement with Bioprojet SCR to acquire exclusive rights for Investigational Medicinal Product, SCD-044
    • Entered into a licensing deal with China Medical System Holdings Limited (CMS) to develop and commercialize multiple products in Mainland China, Hong Kong, Macao, and Taiwan
    • Orphan Drug Designation received from the US FDA for SPARCs neonatal seizures drug, Phenobarbital
    • Orphan Drug Designation received from the US FDA for SPARCs Chronic Myeloid Leukemia drug , SCO-088
    • NDA for Taclantis ® (Paclitaxel Injection Concentrate for Suspension) accepted by US FDA for review
    • Entered into collaboration with HitGen for Innovative Drug Discovery Research
  •  

    2018

    • Entered into collaboration with Schrödinger to accelerate Neurodegeneration Drug Development Programs
    • Positive top line results reported for the pivotal bioequivalence study of Taclantis ® (Paclitaxel Injection Concentrate for Suspension)
    • US FDA approved Xelpros ® for the treatment of open-angle glaucoma or ocular hypertension
  •  

    2017

    • Secured funding of up to Rs. 500 crores through Preferential Allotment of warrants convertible into equity shares
  •  

    2016

    • Raised Rs. 250 crores through Rights Issue
  •  

    2015

    • Entered into research collaboration in the field of Oncology with US University
    • Launched Bevetex™ (PICS) in India
  •  

    2014

    • US rights for Xelpros™ licensed to a subsidiary of Sun Pharma
  •  

    2013

    • Filed NDA for Xelpros™ with USFDA
    • Initiated development of SUN - 597
    • Initiated development of SUN - 597
  •  

    2012

    • 1st NDA filed with USFDA for Elepsia™ XR
    • Raised Rs. 200 crores through Rights Issue
  •  

    2007

    • Innovative R&D business was demerged from Sun Pharmaceutical Industries Limited to focus on innovative drug research
    • Listed on Bombay Stock Exchange and National Stock Exchange of India
  •  

    2006

    • SPARC is founded in Vadodara, India
  •  

    2006

    • SPARC is founded in Vadodara, India

Our Company

  • Who we are
  • history
  • Culture
  • board of directors
  • Leadership team

Our Research

  • Therapeutic focus
  • Delivery Technologies
  • Research Programs
  • R&D Pipeline

Investor Relations

  • Financials
  • Announcements & Disclosures
  • Shareholding pattern
  • Listing Information

Quick Links

Quick Links

  • Business Development
  • Investors
  • Media
  • Careers

Social Connect

  • twitter
  • linkedin

Employee Portal »

Copyright © 2019. Sun Pharma Advanced Research Company Ltd. All rights reserved.
Terms of Use  |   Archival Policy   |   Sitemap
Site Credits